Determination of Prostate-specific Antigen in Capillary Blood (PSA-Cap)

Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Oct 2, 2024

Keywords

ClinConnect Summary

The PSA-Cap study is looking into a new way to measure a substance called prostate-specific antigen (PSA) in men, which can help detect prostate cancer. This study will compare PSA levels measured from a traditional blood draw (venipuncture) to those taken from a small drop of blood from a fingertip (capillary blood). Researchers are also testing how long these blood samples can be kept at room temperature without affecting the results.

Men between the ages of 45 and 70 who agree to participate and provide consent for PSA testing may be eligible for this trial. Participants will provide blood samples and may be asked questions about their health. It’s important to note that those who cannot give consent will not be included in the study. If you join the study, you’ll help researchers understand if this new method of blood testing can be just as effective as the standard method, which could make testing easier for many men in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Men aged from 45 to 70 years
• • Informed consent for PSA measurement for prostate cancer screening
• Exclusion Criteria:
• • Patients unable to give consent